EditorialTreatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids
References (15)
- et al.
Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future
Chest
(1996) Idiopathic pulmonary fibrosisdiagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS)
Am J Respir Crit Care Med
(2000)- Flaherty KR, Toews GB, Lynch JP III, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of...
- et al.
A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis
Am Rev Respir Dis
(1986) - et al.
Idiopathic pulmonary fibrosisprogress in understanding its pathogenesis and implications for therapy
Ann Intern Med
(2001) NSIP, UIP, and the ABCs of idiopathic interstitial pneumonias
Eur Respir J
(1998)- et al.
Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification
Am J Respir Crit Care Med
(1998)
Cited by (32)
Idiopathic interstitial pneumonias
2019, Difficult to Diagnose Rare Diffuse Lung DiseaseTargeting of discoidin domain receptor 2 (DDR2) prevents myofibroblast activation and neovessel formation during pulmonary fibrosis
2016, Molecular TherapyCitation Excerpt :IPF patients have a median survival of ∼2–3 years after diagnosis because of an irreversible loss of lung function and respiratory failure.1 Although a variety of inflammatory insults are associated with the development of IPF, an undeniable fact is that this type fibrotic disorder is clinically recalcitrant to treatment with immunosuppressive agents,2 leading to the recent shift of concept for IPF treatment away from anti-inflammation toward antifibrosis.3 However, although there has been a huge rise in clinical trials with antifibrotic drugs during the past decade, it was until recently that two pharmacological agents were approved for the treatment of moderate IPF.4
Idiopathic Interstitial Pneumonias
2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth EditionPivotal role of cathepsin K in lung fibrosis
2004, American Journal of PathologyCitation Excerpt :A number of experimental approaches have been investigated in clinical trials including the modulation of key cytokines and growth factors, and treatment with corticosteroids or immunosuppressants. In a number of patients these have little effect on clinical outcome.46–48 Therefore, alternative approaches to prevent the development of lung fibrosis should be explored.49
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
2024, Nature BiotechnologyEffects of panax notoginseng saponin on the pathological ultrastructure and serum IL-6 and IL-8 in pulmonary fibrosis in rabbits
2018, Journal of Cellular Biochemistry